Download PDF
Dtsch Med Wochenschr 2013; 138(41): 2098-2103
DOI: 10.1055/s-0033-1349610
Übersicht | Review article
Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Behandlung von Lebermetastasen des kolorektalen Karzinoms

Treatment of colorectal liver metastases
G. Folprecht
1   Universitätskrebszentrum / Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus, Dresden
› Author Affiliations
Further Information

Publication History

05 September 2013

19 September 2013

Publication Date:
01 October 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Behandlung von Patienten mit kolorektalen Lebermetastasen hat sich durch die Möglichkeiten der Resektion und der zunehmend effektiveren systemischen Therapie verändert und stellt ein Modell für die Therapie von anderen Situationen mit limitierter Metastasierung dar. Weil die Metastasenresektion mit einer Verbesserung des Überlebens assoziiert ist, sollte die Therapie Patienten mit einer Lebermetastasierung in einem Team mit einem erfahrenen Leberchirurgen beraten werden. Möglichkeiten zum Erreichen oder Verbessern der Resektabilität sind insbesondere die „Konversions“- Chemotherapie, aber auch z. B. die Portalvenenembolisation oder zweizeitige Resektionen.

Abstract

The treatment of patients with colorectal liver metastases has been changed with the improved surgical techniques and the increasingly effective systemic therapy. It represents therefore a model for the therapy in other situations with limited metastatic disease. Because the overall survival is associated with metastasectomy, the treatment of patients with liver metastases should be discussed in a team with experienced liver surgeons. Options to increase or to achieve resectability are especially “conversion” chemotherapy, but also i. e. portal vein embolization and two step resections.

Schlüsselwörter

kolorektales Karzinom - Lebermetastasen - neoadjuvante Therapie - Chemotherapie - interdisziplinäre Therapie

Keywords

colorectal cancer - liver metastases - neoadjuvant therapy - chemotherapy - multidisciplinary therapy
 

  • Literatur

  • 1 Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634
    CrossrefPubMedGoogle Scholar
  • 2 Auer RC, White RR, Kemeny NE et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116: 1502-1509
    CrossrefPubMedGoogle Scholar
  • 3 Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 2006; 24: 3939-3945
    CrossrefPubMedGoogle Scholar
  • 4 Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-1546
    CrossrefPubMedGoogle Scholar
  • 5 Brouquet A, Abdalla EK, Kopetz S et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29: 1083-1090
    CrossrefPubMedGoogle Scholar
  • 6 Cosimelli M, Golfieri R, Cagol PP et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010; 103: 324-331
    CrossrefPubMedGoogle Scholar
  • 7 Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33: 11-17
    CrossrefPubMedGoogle Scholar
  • 8 De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer. Lancet Oncol 2010; 11: 753-762
    CrossrefPubMedGoogle Scholar
  • 9 Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME Study. J Clin Oncol 2010; 28: 4697-4705
    CrossrefPubMedGoogle Scholar
  • 10 Elias D, Liberale G, Vernerey D et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005; 12: 900-909
    CrossrefPubMedGoogle Scholar
  • 11 Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676
    CrossrefPubMedGoogle Scholar
  • 12 Falcone A, Cremolini C, Masi G et al. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts). J Clin Oncol (Meeting Abstracts) 2013; 31: 3505
    PubMedGoogle Scholar
  • 13 Fiorentini G, Aliberti C, Tilli M et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancery. Anticancer Res 2012; 32: 1387-1395
    PubMedGoogle Scholar
  • 14 Floriani I, Torri V, Rulli E et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31: 19-31
    CrossrefPubMedGoogle Scholar
  • 15 Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319
    CrossrefPubMedGoogle Scholar
  • 16 Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47
    CrossrefPubMedGoogle Scholar
  • 17 Folprecht G, Gruenberger T, Bechstein W et al. Cetuximab and chemotherapy in the treatment of patients with initially „nonresectable“ colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial. J Clin Oncol (Meeting Abstracts) 2013; 31: 3538
    PubMedGoogle Scholar
  • 18 Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT). Lancet 2013; 381: 303-312
    CrossrefPubMedGoogle Scholar
  • 19 Heinemann V, Fischer von Weikersthal L, Decker T et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol (Meeting Abstracts) 2013; 31: LBA3506
    PubMedGoogle Scholar
  • 20 Jones RP, Vauthey JN, Adam R et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 2012; 99: 1263-1269
    CrossrefPubMedGoogle Scholar
  • 21 Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683
    CrossrefPubMedGoogle Scholar
  • 22 Lam VW, Pang T, Laurence JM et al. A systematic review of repeat hepatectomy for recurrent colorectal liver metastases. J Gastrointest Surg 2013; 17: 1312-1321
    CrossrefPubMedGoogle Scholar
  • 23 Malka D, Paris E, Caramella C et al. Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE). J Clin Oncol (Meeting Abstracts) 2010; 28: 3558
    PubMedGoogle Scholar
  • 24 Mentha G, Roth AD, Terraz S et al. „Liver first“ approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg 2008; 25: 430-435
    CrossrefPubMedGoogle Scholar
  • 25 Mitry E, Fields AL, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911
    CrossrefPubMedGoogle Scholar
  • 26 Morris EJ, Forman D, Thomas JD et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97: 1110-1118
    CrossrefPubMedGoogle Scholar
  • 27 Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983). Lancet 2008; 371: 1007-1016
    CrossrefPubMedGoogle Scholar
  • 28 Nordlinger B, Sorbye H, Glimelius B et al. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. J Clin Oncol (Meeting Abstracts) 2012; 30: 3508
    PubMedGoogle Scholar
  • 29 Oliner KS, Douillard JY, Siena S et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol (Meeting Abstracts) 2013; 31: 3511
    PubMedGoogle Scholar
  • 30 Primrose JN, Falk S, Finch-Jones M et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer. J Clin Oncol (Meeting Abstracts) 2013; 31: 3504
    PubMedGoogle Scholar
  • 31 Ruers T, Punt C, Van Coevorden F et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases. Ann Oncol 2012; 23: 2619-2626
    CrossrefPubMedGoogle Scholar
  • 32 Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180
    CrossrefPubMedGoogle Scholar
  • 33 Schwartzberg LS, Rivera F, Karthaus M et al. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol (Meeting Abstracts) 2013; 31: 3631
    CrossrefPubMedGoogle Scholar
  • 34 Selzner M, Hany TF, Wildbrett P et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg 2004; 240: 1027-1034
    CrossrefPubMedGoogle Scholar
  • 35 Siperstein AE, Berber E, Ballem N et al. Survival after radiofrequency ablation of colorectal liver metastases. Ann Surg 2007; 246: 559-565
    CrossrefPubMedGoogle Scholar
  • 36 Sorbye H, Mauer M, Gruenberger T et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 2012; 255: 534-539
    CrossrefPubMedGoogle Scholar
  • 37 Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC). Br J Cancer 2006; 94: 798-805
    CrossrefPubMedGoogle Scholar
  • 38 Spelt L, Andersson B, Nilsson J et al. Prognostic models for outcome following liver resection for colorectal cancer metastases. Eur J Surg Oncol 2012; 38: 16-24
    CrossrefPubMedGoogle Scholar
  • 39 Van Cutsem E, Köhne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019
    CrossrefPubMedGoogle Scholar
  • 40 Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072
    Google Scholar
  • 41 Wiering B, Krabbe PF, Dekker HM et al. The role of FDG-PET in the selection of patients with colorectal liver metastases. Ann Surg Oncol 2007; 14: 771-779
    CrossrefPubMedGoogle Scholar
  • 42 Wiering B, Oyen WJ, Adang EM et al. Long-term global quality of life in patients treated for colorectal liver metastases. Br J Surg 2011; 98: 565-571
    CrossrefPubMedGoogle Scholar
  • 43 Wieser M, Sauerland S, Arnold D et al. Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer. BMC Cancer 2010; 10: 309
    CrossrefPubMedGoogle Scholar
  • 44 Ye LC, Liu TS, Ren L et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 2013; 31: 1931-1938
    CrossrefPubMedGoogle Scholar